[Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].
Rinsho Ketsueki
; 65(4): 265-271, 2024.
Article
in Ja
| MEDLINE
| ID: mdl-38684437
ABSTRACT
Hematopoietic cell transplantation (HCT) is considered a curative treatment for hematological malignancies. However, HCT recipients often face complications such as graft-versus-host disease (GVHD) and disease relapse. Clinical factors like age and HLA disparity are recognized as risks for GVHD. Notably, sex-mismatched HCT, particularly with female donors and male recipients (FâM), is reported to increase the risk of chronic GVHD. This adverse effect of FâM HCT is thought to result from allogeneic immune response against minor histocompatibility antigens encoded on the Y-chromosome of a male recipient (HY-antigens). Indeed, antibodies against HY-antigens (HY-Abs) were detected three months after FâM HCT, and the cumulative number of HY-Abs was significantly associated with increased risks of chronic GVHD and non-relapse mortality. This review focuses on FâM HCT, shedding light on its impact in several clinical settings and presenting clinical evidence of its allogeneic response, encompassing GVHD and graft-versus-leukemia (GVL) effects. Additionally, potential clinical options to mitigate adverse effects in FâM HCT will be discussed. Further investigation is required to improve clinical outcomes and understand allogenic immunological reconstitution after FâM HCT.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tissue Donors
/
Transplantation, Homologous
/
Hematopoietic Stem Cell Transplantation
/
Graft vs Leukemia Effect
/
Graft vs Host Disease
Limits:
Female
/
Humans
/
Male
Language:
Ja
Journal:
Rinsho Ketsueki
Year:
2024
Type:
Article